RxDoctor Payments Data

Stephen de Souza, MD

Retina Specialist · Phoenix, AZNPI 1548232820

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (52.5%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 86.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $53,607 and has fallen 95.5% since, to $2,389 in 2025.

$95,284in general payments, 2019–2025

Across 478 payments — averaging $199.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$83K
  • Alimera Sciences, Inc.$3K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Bausch & Lomb Americas Inc.$1K
  • Genentech USA, Inc.$1K
  • AbbVie$1K
  • plus $4K from 19 others
$867,701in research payments, 2019–2025

Across 223 payments — averaging $3891.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ocular Therapeutix, Inc.$485K
  • Boehringer Ingelheim$377K
  • Boehringer Ingelheim International GmbH$5K

What the payments were for

  • Food & beverage$12,86714%
  • Education$150%
  • Gifts$190%
  • Ownership interest$32,38334%
  • Other$50,00052%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,284 in reported general payments places this provider in the 80th percentile of 30 retina specialist providers in Arizona.

See all retina specialist providers in Arizona

Medicare billing

Part B allowed, 2024
$3,283,086
Medicare patients
1,619
Services billed
30,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate383$17,887
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol35$4,849
Brimonidine Tartrate113$4,034
Ofloxacin278$2,802
Timolol Maleate234$2,753
Ketorolac Tromethamine96$2,320
Latanoprost135$1,857
Atropine Sulfate23$801
Dorzolamide Hcl45$747
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat32$432
Prednisone12$63

Paid to pharmacies, not to this prescriber.

Other retina specialist in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →